Condition: Central Nervous System Lymphoma · Sponsor: University of Utah
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
This description comes directly from the study's public registry record.
Rachel Kingsford · 801-585-0115 · Rachel.Kingsford@hci.utah.edu
Narendranath Epperla, MD, MS · 801-585-0255 · naren.epperla@hci.utah.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center at Jefferson | Philadelphia, Pennsylvania, United States | Recruiting |
| Brown University Health Rhode Island Hospital | Providence, Rhode Island, United States | Not Yet Recruiting |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06607549